↓ Skip to main content

Taxation as prevention and as a treatment for obesity: the case of sugar-sweetened beverages.

Overview of attention for article published in Current Pharmaceutical Design, January 2011
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (93rd percentile)
  • High Attention Score compared to outputs of the same age and source (91st percentile)

Mentioned by

blogs
2 blogs
policy
1 policy source
twitter
1 X user

Readers on

mendeley
112 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Article details
Title
Taxation as prevention and as a treatment for obesity: the case of sugar-sweetened beverages.
Published in
Current Pharmaceutical Design, January 2011
DOI 10.2174/138161211795656783
Pubmed ID
Authors
Abstract

The contemporary American food environment makes energy-dense, nutrient-poor foods and beverages the "default" option for most consumers. Economic interventions like taxes can shift the relative prices of unhealthy foods to nudge consumers towards healthier options. Beverages with added sugar are a good starting point for food taxation; they constitute over 10 percent of caloric intake nationwide and provide little or no nutritional value. Current levels of taxation on sugar-sweetened beverages (SSBs) are too low to affect consumer behavior, but the implementation of a penny-per-ounce excise tax could lead to substantial public health benefits. Current estimates predict that a tax that raised the cost of SSBs by 20 percent could lead to an average reduction of 3.8 pounds per year for adults, causing the prevalence of obesity to decline from 33 to 30 percent. SSB taxes would also generate considerable revenue for public health and obesity prevention programs. Although the beverage industry is fighting such taxes with massive lobbying and public relations campaigns, support for the policies is increasing, especially when revenue is earmarked for obesity prevention.

Login to access the Attention Digest and the Sentiment Analysis related to this output.

Timeline Attention over time Attention Score history
Login to access the full charts related to this output.
Activity
Login to access the full charts related to this output.
X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley demographics

Mendeley demographics

The data shown below were compiled from readership statistics for 112 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Login to view Mendeley reader trends over time.

Geographical breakdown

Geographical breakdown
Country Count As %
United States 1 <1%
Iran, Islamic Republic of 1 <1%
United Kingdom 1 <1%
France 1 <1%
Brazil 1 <1%
Unknown 107 96%

Demographic breakdown

Readers by professional status
Readers by professional status Count As %
Student > Master 18 16%
Researcher 17 15%
Student > Bachelor 11 10%
Student > Ph. D. Student 11 10%
Student > Postgraduate 9 8%
Other 22 20%
Unknown 24 21%
Readers by discipline
Readers by discipline Count As %
Medicine and Dentistry 27 24%
Economics, Econometrics and Finance 13 12%
Social Sciences 12 11%
Nursing and Health Professions 9 8%
Agricultural and Biological Sciences 7 6%
Other 17 15%
Unknown 27 24%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 16. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 June 2014.
All research outputs
#2,875,815
of 34,526,284 outputs
Outputs from Current Pharmaceutical Design
#257
of 4,578 outputs
Outputs of similar age
#15,120
of 253,673 outputs
Outputs of similar age from Current Pharmaceutical Design
#13
of 145 outputs
Altmetric has tracked 34,526,284 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,578 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.8. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 253,673 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 145 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 91% of its contemporaries.